Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 /PRNewswire/ ... uses next generation sequencing technology to empower cancer care, ... as chief executive officer. In his expanded role ... for all strategy, business expansion and worldwide operations effective ... as Strand,s chairman and CEO since its founding in ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences Ltd. ... on the treatment of dementia, today announced that ... July 22 at 5:45 p.m. EDT following its ... Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , Chief ...
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... identified, search engines are leading the way for consumers ... related to the efficacy of these search engines, among ... soon and why could this happen? , ,If search ... todays search results, which often include a great deal ...
... mentioned my first law of softwareany mildly successful software program ... operating system. Youve seen it. The e-mail system that gets ... in version three and so on. The ERP system that ... for this kind of behavior is the browser. , ,So ...
... campaign season, and you've been poked and prodded by television ... John Kerry drank a beer at your neighborhood bar and ... Dick Cheney was spotted more in Wisconsin in 2004 than ... years. John Edwards has been in the state so often ...
Cached Biology Technology:When search engines collide 2When search engines collide 3When search engines collide 4The first law of software 2The first law of software 3Twenty ways you can tell this campaign has finally pushed you over the edge 2
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... such as schizophrenia, major depression and cancer are ... dysfunctional genes. A novel computational biology method developed ... PhD, http://www.njit.edu/news/2008/2008-367.php , associate professor in NJIT,s ... a way to uncover the critical genes responsible ...
... WEST LAFAYETTE, Ind. Although research has linked inbreeding ... of animals, a new study finds it plays no ... Purdue University researchers recently examined 2,000 adult and ... deformities, mainly consisting of missing, extra or dwarfed digits ...
... NEW YORK, NY (October 28, 2008) The first ... exploring the role of hospital touch surfaces in the ... researchers reported their findings in a poster session at ... in Washington, D.C. on Tuesday, October 28. The ...
Cached Biology News:NJIT professor finds engineering technique to identify disease-causing genes 2Study rules out inbreeding as cause of amphibian deformities 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
Biology Products: